Education Library

“The precarious balance between bleeding and thrombosis in patients with p-LVAD support is often the primary reason that patients’ outcomes are jeopardized,” write the authors of this article, which discusses anticoagulation strategies and anticoagulant management in the setting of Protected PCI.

This article describes pre-procedural preparation, with a particular focus on imaging techniques for screening and guiding vascular access in patients undergoing Protected PCI.

Jason Richard provides a tip-to-toe review of the key features of the Impella RP Flex with SmartAssist®.

Michael Galvin, a clinical educator at Abiomed, discusses how to identify Impella components and measure Impella position using echocardiography.

Michael Galvin discusses how to measure the position of the Impella 5.5® with SmartAssist® using echocardiography.

Fadi Al-Rashid, MD, discusses his publication on standard pre-procedural clinical workup for Protected PCI.

Michael Galvin describes the 4 major views that make up a full echocardiogram as well as the role of color and spectral Doppler in assessing Impella® position.

Prof. Christophe Vandenbriele, MD, urges caution and the need for context when drawing conclusions from retrospective analyses in critically ill patients with cardiogenic shock.

Birgit Markus, MD, discusses data on the impact of Impella® heart pump support on hemodynamics and renal function in patients with cardiogenic shock.

Jürgen Leick, MD, discusses his paper on optimizing patient selection in high-risk protected percutaneous coronary intervention.

Prof. Dr. Christophe Vandenbriele discusses his recently published paper on anticoagulation in patients underoing Protected PCI procedures.

Members of the heart team at Tampa General Hospital discuss their early experience with the Impella RP Flex™ with SmartAssist®.

Prof. Karim Ibrahim discusses his article describing best practices for handling high-risk patients in the cardiac catheterization laboratory.

Vasileios Panoulas, MD, discusses a pooled analysis of factors predicting outcomes at 90 days in high-risk PCI patients.

Learn more about the data and differences between part I and part II from the York data analysis.